다발성 골수종 시장 규모, 점유율, 성장 및 세계 산업 분석 : 종류별, 용도별, 지역별 인사이트와 예측(2026-2034년)

Growth Factors of multiple myeloma Market

The global multiple myeloma market was valued at USD 29.24 billion in 2025 and is projected to grow from USD 31.00 billion in 2026 to USD 44.19 billion by 2034, registering a CAGR of 6.10% during the forecast period. North America dominated the market with a 58.28% share in 2025, supported by higher disease diagnosis rates, strong adoption of advanced therapeutics, and the presence of leading oncology companies.

Multiple myeloma (MM) is a rare but severe form of blood cancer characterized by the uncontrolled proliferation of plasma cells. If left untreated, the disease can be fatal. Rising awareness of disease symptoms, earlier diagnosis, and rapid advancements in targeted and immunotherapy-based treatments have significantly improved disease management, driving market growth globally.

Market Snapshot & Key Highlights

• 2025 Market Size: USD 29.24 billion
• 2026 Market Size: USD 31.00 billion
• 2034 Market Size: USD 44.19 billion
• CAGR: 6.10%
• Dominant Region: North America (58.28% share in 2025)
• Leading Drug Class: Immunomodulators

Market Trends

Strong Pipeline Candidates Driving Growth

One of the major trends shaping the multiple myeloma market is the robust pipeline of novel therapeutics. Pharmaceutical companies are heavily investing in R&D to address unmet clinical needs. Several promising pipeline candidates are in various stages of clinical development. For instance, Regeneron's REGN5458 (BCMAXCD3) has shown positive clinical outcomes, highlighting the growing role of bispecific antibodies and targeted therapies. These advancements are expected to significantly contribute to market expansion during the forecast period.

Market Drivers

Increasing Prevalence of Multiple Myeloma

The rising prevalence of blood cancers, including multiple myeloma, is a key driver of market growth. Although MM is classified as a rare cancer, it accounts for a substantial number of cancer cases worldwide. According to Cancer Network statistics, approximately 130,000 cases of multiple myeloma were reported globally in 2016, and incidence rates continue to rise. Improved diagnostic capabilities and increased awareness have led to higher detection rates, thereby increasing demand for effective treatment options.

Rising Product Launches and Regulatory Approvals

Continuous R&D efforts have resulted in frequent product launches and regulatory approvals, enhancing treatment availability. For example, in March 2020, the U.S. FDA approved Sarclisa (isatuximab-irfc) in combination therapy for patients with relapsed or refractory multiple myeloma. Although cure rates remain limited, improved disease management and better prognosis are encouraging more patients to seek treatment, boosting market revenue.

Market Restraint

High Cost of Treatment

Despite therapeutic advancements, high treatment costs remain a significant barrier, especially in developing economies. Annual treatment costs can range from USD 5,800 for cyclophosphamide to nearly USD 192,000 for Pomalyst, limiting access to advanced therapies. Lack of reimbursement coverage, limited awareness, and inadequate payment mechanisms further restrict treatment adoption in emerging markets.

Segmentation Analysis

By Drug Class

The immunomodulators segment dominated the market, accounting for 65.07% share in 2026. Drugs such as Revlimid (Celgene/Bristol Myers Squibb) have played a crucial role in achieving positive treatment outcomes. Other important segments include proteasome inhibitors, anti-CD38 monoclonal antibodies, alkylating agents, and emerging drug classes such as XPO1 inhibitors.

By Distribution Channel

Hospital pharmacies held the largest market share at 58.67% in 2026, due to the high use of intravenously administered therapies and the need for controlled clinical settings. Retail pharmacies registered slower growth, while online pharmacies are expected to grow steadily due to convenience and easier prescription fulfillment.

Regional Analysis

• North America remains the leading region due to high diagnosis rates, strong healthcare expenditure, and advanced therapeutics adoption.
• Europe benefits from increasing regulatory approvals and longer patent expiry timelines.
• Asia Pacific shows strong growth potential, supported by large patient populations and approvals of key drugs such as DARZALEX in Japan.
• Latin America and Middle East & Africa are in early growth stages but are expected to expand with improving healthcare infrastructure.

Competitive Landscape

The market is highly competitive, led by major oncology players such as Takeda, Bristol Myers Squibb, Amgen, Janssen, Genentech, AbbVie, Sanofi, and Karyopharm. Companies are focusing on product diversification, pipeline expansion, and regulatory approvals to strengthen their market position.

Conclusion

The global multiple myeloma market, valued at USD 29.24 billion in 2025, grew to USD 31.00 billion in 2026 and is projected to reach USD 44.19 billion by 2034. Market growth is driven by rising disease prevalence, strong R&D pipelines, increasing product approvals, and improved treatment outcomes. While high treatment costs remain a challenge, continuous innovation and expanding access to advanced therapies are expected to support sustained market growth during the forecast period.

Segmentation By Drug Class

• Immunomodulators
• Proteasome Inhibitor
• Anti-CD38 Monoclonal Antibody
• Alkylating Agents
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies & Drug Stores
• Online Pharmacies

By Geography

• North America (U.S. and Canada)
• Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)
• Asia-Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia-Pacific)
• Latin America (Brazil, Mexico, and the Rest of Latin America)
• Middle East & Africa (South Africa, GCC, and the Rest of Middle East & Africa)

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities

4. Key Insights

• 4.1. Prevalence of Multiple Myeloma - by Key Countries - 2025
• 4.2. Pipeline Analysis
• 4.3. Key Industry Developments
• 4.4. Regulatory Scenario, by Key Regions
• 4.5. Analysis Of Economic Burden of Multiple Myeloma Treatment
• 4.6. New Product Launches
• 4.7. Overview of Emerging Treatments for Multiple Myeloma

5. Global Multiple Myeloma Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Key Findings / Summary
• 5.2. Market Analysis, Insights and Forecast - By Drug Class
  • 5.2.1. Immunomodulators
  • 5.2.2. Proteasome Inhibitor
  • 5.2.3. Anti-CD38 Monoclonal Antibody
  • 5.2.4. Alkylating Agents
  • 5.2.5. Others
• 5.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.3.1. Hospital Pharmacies
  • 5.3.2. Retail Pharmacies & Drug Stores
  • 5.3.3. Online Pharmacies
• 5.4. Market Analysis, Insights and Forecast - By Region
  • 5.4.1. North America
  • 5.4.2. Europe
  • 5.4.3. Asia Pacific
  • 5.4.4. Latin America
  • 5.4.5. Middle East & Africa

6. North America Multiple Myeloma Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Key Findings / Summary
• 6.2. Market Analysis - By Drug Class
  • 6.2.1. Immunomodulators
  • 6.2.2. Proteasome Inhibitor
  • 6.2.3. Anti-CD38 Monoclonal Antibody
  • 6.2.4. Alkylating Agents
  • 6.2.5. Others
• 6.3. Market Analysis - By Distribution Channel
  • 6.3.1. Hospital Pharmacies
  • 6.3.2. Retail Pharmacies & Drug Stores
  • 6.3.3. Online Pharmacies
• 6.4. Market Analysis - By Country
  • 6.4.1. U.S.
  • 6.4.2. Canada

7. Europe Multiple Myeloma Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Key Findings / Summary
• 7.2. Market Analysis - By Drug Class
  • 7.2.1. Immunomodulators
  • 7.2.2. Proteasome Inhibitor
  • 7.2.3. Anti-CD38 Monoclonal Antibody
  • 7.2.4. Alkylating Agents
  • 7.2.5. Others
• 7.3. Market Analysis - By Distribution Channel
  • 7.3.1. Hospital Pharmacies
  • 7.3.2. Retail Pharmacies & Drug Stores
  • 7.3.3. Online Pharmacies
• 7.4. Market Analysis - By Country/ sub-region
  • 7.4.1. U.K.
  • 7.4.2. Germany
  • 7.4.3. France
  • 7.4.4. Spain
  • 7.4.5. Italy
  • 7.4.6. Scandinavia
  • 7.4.7. Rest of Europe

8. Asia pacific Multiple Myeloma Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Key Findings / Summary
• 8.2. Market Analysis - By Drug Class
  • 8.2.1. Immunomodulators
  • 8.2.2. Proteasome Inhibitor
  • 8.2.3. Anti-CD38 Monoclonal Antibody
  • 8.2.4. Alkylating Agents
  • 8.2.5. Others
• 8.3. Market Analysis - By Distribution Channel
  • 8.3.1. Hospital Pharmacies
  • 8.3.2. Retail Pharmacies & Drug Stores
  • 8.3.3. Online Pharmacies
• 8.4. Market Analysis - By Country/ sub-region
  • 8.4.1. Japan
  • 8.4.2. China
  • 8.4.3. India
  • 8.4.4. Australia
  • 8.4.5. Southeast Asia
  • 8.4.6. Rest of Asia Pacific

9. Latin America Multiple Myeloma Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Key Findings / Summary
• 9.2. Market Analysis - By Drug Class
  • 9.2.1. Immunomodulators
  • 9.2.2. Proteasome Inhibitor
  • 9.2.3. Anti-CD38 Monoclonal Antibody
  • 9.2.4. Alkylating Agents
  • 9.2.5. Others
• 9.3. Market Analysis - By Distribution Channel
  • 9.3.1. Hospital Pharmacies
  • 9.3.2. Retail Pharmacies & Drug Stores
  • 9.3.3. Online Pharmacies
• 9.4. Market Analysis - By Country/ sub-region
  • 9.4.1. Brazil
  • 9.4.2. Mexico
  • 9.4.3. Rest of Latin America

10. Middle East & Africa Multiple Myeloma Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Key Findings / Summary
• 10.2. Market Analysis - By Drug Class
  • 10.2.1. Immunomodulators
  • 10.2.2. Proteasome Inhibitor
  • 10.2.3. Anti-CD38 Monoclonal Antibody
  • 10.2.4. Alkylating Agents
  • 10.2.5. Others
• 10.3. Market Analysis - By Distribution Channel
  • 10.3.1. Hospital Pharmacies
  • 10.3.2. Retail Pharmacies & Drug Stores
  • 10.3.3. Online Pharmacies
• 10.4. Market Analysis - By Country/ sub-region
  • 10.4.1. GCC Countries
  • 10.4.2. South Africa
  • 10.4.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Key Industry Developments
• 11.2. Global Market Share Analysis (2017)
• 11.3. Competition Dashboard
• 11.4. Comparative Analysis - Major Players
• 11.5. Company Profiles (Overview, Products & services, SWOT analysis, Recent developments, strategies, financials (based on availability))
  • 11.5.1. Takeda Pharmaceutical Company Limited
    • 11.5.1.1. Overview,
    • 11.5.1.2. Products & services,
    • 11.5.1.3. SWOT analysis,
    • 11.5.1.4. Recent developments,
    • 11.5.1.5. strategies,
    • 11.5.1.6. financials (based on availability)
  • 11.5.2. Novartis AG
    • 11.5.2.1. Overview,
    • 11.5.2.2. Products & services,
    • 11.5.2.3. SWOT analysis,
    • 11.5.2.4. Recent developments,
    • 11.5.2.5. strategies,
    • 11.5.2.6. financials (based on availability)
  • 11.5.3. Teva Pharmaceutical Industries Ltd.
    • 11.5.3.1. Overview,
    • 11.5.3.2. Products & services,
    • 11.5.3.3. SWOT analysis,
    • 11.5.3.4. Recent developments,
    • 11.5.3.5. strategies,
    • 11.5.3.6. financials (based on availability)
  • 11.5.4. Bristol Myers Squibb Company
    • 11.5.4.1. Overview,
    • 11.5.4.2. Products & services,
    • 11.5.4.3. SWOT analysis,
    • 11.5.4.4. Recent developments,
    • 11.5.4.5. strategies,
    • 11.5.4.6. financials (based on availability)
  • 11.5.5. Amgen Inc.
    • 11.5.5.1. Overview,
    • 11.5.5.2. Products & services,
    • 11.5.5.3. SWOT analysis,
    • 11.5.5.4. Recent developments,
    • 11.5.5.5. strategies,
    • 11.5.5.6. financials (based on availability)
  • 11.5.6. ONO PHARMACEUTICAL CO., LTD.
    • 11.5.6.1. Overview,
    • 11.5.6.2. Products & services,
    • 11.5.6.3. SWOT analysis,
    • 11.5.6.4. Recent developments,
    • 11.5.6.5. strategies,
    • 11.5.6.6. financials (based on availability)
  • 11.5.7. Janssen Pharmaceuticals, Inc.
    • 11.5.7.1. Overview,
    • 11.5.7.2. Products & services,
    • 11.5.7.3. SWOT analysis,
    • 11.5.7.4. Recent developments,
    • 11.5.7.5. strategies,
    • 11.5.7.6. financials (based on availability)
  • 11.5.8. Genentech, Inc. (F. Hoffmann-La Roche Ltd)
    • 11.5.8.1. Overview,
    • 11.5.8.2. Products & services,
    • 11.5.8.3. SWOT analysis,
    • 11.5.8.4. Recent developments,
    • 11.5.8.5. strategies,
    • 11.5.8.6. financials (based on availability)
  • 11.5.9. CELGENE CORPORATION (Bristol Myers Squibb Company)
    • 11.5.9.1. Overview,
    • 11.5.9.2. Products & services,
    • 11.5.9.3. SWOT analysis,
    • 11.5.9.4. Recent developments,
    • 11.5.9.5. strategies,
    • 11.5.9.6. financials (based on availability)
  • 11.5.10. AbbVie Inc.
    • 11.5.10.1. Overview,
    • 11.5.10.2. Products & services,
    • 11.5.10.3. SWOT analysis,
    • 11.5.10.4. Recent developments,
    • 11.5.10.5. strategies,
    • 11.5.10.6. financials (based on availability)
  • 11.5.11. Sanofi
    • 11.5.11.1. Overview,
    • 11.5.11.2. Products & services,
    • 11.5.11.3. SWOT analysis,
    • 11.5.11.4. Recent developments,
    • 11.5.11.5. strategies,
    • 11.5.11.6. financials (based on availability)
  • 11.5.12. Other Prominent Players
    • 11.5.12.1. Overview,
    • 11.5.12.2. Products & services,
    • 11.5.12.3. SWOT analysis,
    • 11.5.12.4. Recent developments,
    • 11.5.12.5. strategies,
    • 11.5.12.6. financials (based on availability)

12. Strategic Recommendation